TNF Inhibitor denied as not medically necessary by OptumRx?

Adalimumab biosimilar preferred (Cyltezo / Hyrimoz / Adalimumab-adaz). Step therapy from biosimilar. Self-administered — Part D / pharmacy benefit.

OptumRx Continuity of Care provisions for >180-day stable patients. ACR 2019 anti-non-medical-switching position. State step-therapy override laws (NY §4903, TX SB 1216, CA HSC §1367.241).

## Why OptumRx Denied Your TNF Inhibitor as Not Medically Necessary

A medical-necessity denial from OptumRx means the plan's clinical reviewers concluded that your submitted documentation did not satisfy every criterion in OptumRx's coverage policy for this TNF inhibitor. These policies typically require evidence of a confirmed diagnosis, documented disease severity, and failure of or contraindication to specific prior therapies. If any element is missing from the claim record — even if it exists in your chart — the denial will issue automatically.

## Why This Denial Is Frequently Overturned

Medical-necessity denials are among the most commonly reversed on appeal. The reversal rate is high because the clinical information needed to satisfy the policy criteria almost always exists in the patient's medical record — it simply was not included with the prior authorization request. A focused appeal that pulls every relevant chart note, lab result, and prior-treatment record and maps them explicitly to each policy criterion gives the reviewer everything needed to approve the claim.

## Federal Appeal Rights

Under ERISA §503, your plan must provide a full-and-fair review, supply its complete claim file, and explain the specific clinical basis for the denial in plain language. Under ACA §2719, you may escalate to an independent external review if the internal appeal is denied — the external reviewer applies objective clinical standards, not just the plan's internal policy. The external-review window is generally 4 months from the date of the adverse benefit determination; confirm the exact deadline on your Explanation of Benefits. Expedited review (72-hour decision) is available when a standard timeline would seriously jeopardize your health or ability to regain maximum function.

## Concrete Appeal Steps and Timeline

1. Request the full claim file and the specific OptumRx clinical coverage policy applied to this denial — you are entitled to both. 2. Read the denial letter line by line and identify each criterion the plan says was not met. 3. Collect the medical records that address each unmet criterion. 4. File a Level 1 internal appeal — typically within 180 days of denial — with a complete documentation package. 5. If Level 1 is upheld, file a Level 2 internal appeal (if available) and then immediately proceed to external review.

## Documentation to Gather

• Diagnosis confirmation: Most recent chart notes, specialist evaluations, lab work, imaging, or pathology reports confirming the diagnosis and current disease activity or severity.
• Prior-treatment history: For each therapy the policy requires to have been tried, provide the medication name, start and stop dates, doses used (as documented in the chart), and a clear clinical explanation of why it was discontinued — inadequate response, intolerance, or contraindication.
• Disease-severity documentation: Validated clinical scoring tools, functional assessments, or physician narrative describing the impact of disease on your daily functioning, as recorded in the chart.
• Prescriber medical-necessity letter: A letter from your treating physician addressing each policy criterion directly, explaining why the TNF inhibitor is medically necessary for your specific clinical situation and citing the relevant professional society guideline organization.

## Criteria-Mapping Structure

Obtain the exact text of OptumRx's coverage policy for this drug. Create a table with two columns: the policy requirement verbatim on the left, and the specific chart fact (with record date and source) that satisfies it on the right. Submit this table as part of your appeal letter. This format makes it impossible for the reviewer to claim a criterion was not addressed and significantly reduces the chance of a second denial.